Navigation Links
EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
Date:11/28/2007

iCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU or that Ceplene, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that EpiCept will not receive any significant payments under its agreement with Myriad, the risk that the development of the Company's other apoptosis product candidates will not be successful, the risk that its ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 or EPC 2407 will not be successful, that NP-1 or EPC 2407 will not receive regulatory approval or achieve significant commercial success, the risk that the Company's other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with reliance on additional outside financing to meet its capital requirements, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of its product candidates; the cost, delays and uncertainties associated with its scientific research, product development, clinical trials and regulatory approval process; its history of operating losses since inception; competition; litigation; r
'/>"/>
SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. EpiCept Corporation to Present at the 2007 BIO InvestorForum
2. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
3. EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
5. EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
6. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
7. Brooke Franchise Corporation Announces Selected July Results
8. MedThink Communications Retained by NanoBio Corporation
9. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
10. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... April 17, 2014 By discovering a new mechanism ... a stroke, researchers at UC Irvine and the Salk ... may limit or prevent stroke-induced brain damage. , A ... cause of death and primary reason for disability in ... a stroke and lets blood-borne material into the brain, ...
(Date:4/17/2014)... time online has the potential to ward off depression ... to research published online in The Journals ... . In the article " Internet Use and ... A Longitudinal Analysis ," the authors report that Internet ... 33 percent among their study sample. , Late-life ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... CHERRY HILL, N.J., Sept. 11 Nuvilex, Inc. (OTC ... its joint venture partner, has informed the company that ... its homeopathic remedy for helping to prevent and treat ... The Reme-Flu(TM) formula consists of a two-part protocol. ...
... Bupa,s Latin America and Caribbean,operation -- a division ... the launch of the international Ecuador Challenge, which will,take ... families survive on,average on just $4 a day. Some ... Ecuador until November 29 to build essential health and ...
... , MISSISSAUGA, Ontario, Sept. 11 JAG ... agreement with The Investor Relations Group, Inc. ("IRG"), pursuant to which ... the Company in accordance with the terms of the agreement. As ... to IRG. , , "We are very excited ...
... , , YARDLEY, Pa., Sept. 11 ... soft tissue and skeletal repair of the extremities, announced today that ... Chairman of the Board, effective immediately. , , ... as it moves from product development to commercialization," said Zev Scherl, ...
... , IRVING, Texas, Sept. 11 ... 643 on its third annual Inc. 5000, an exclusive ranking ... most comprehensive look at the most important segment of the ... rental car service Zipcar, and beverage maker Honest Tea are ...
... - HTDS www.htdsmedical.com The company is pleased ... Hope www.mellowhope.com has successfully completed and delivered ... Bangladesh. , In developing countries, over 11 million children ... nearly three quarters of these deaths result from infectious ...
Cached Medicine News:Health News:Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula 2Health News:Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula 3Health News:Bupa Launches its 2009 International Charity Challenge to Help a Rural Community in Ecuador 2Health News:JAG Media Holdings, Inc. Announces Agreement with The Investor Relations Group, Inc. 2Health News:John C. Moran Named CEO at Core Essence Orthopaedics 2Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 2Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 3Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 4Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 5Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 6Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 7Health News:Hard To Treat Diseases (HTDS) MEVAC-A Completes Tender For Bangladesh 2Health News:Hard To Treat Diseases (HTDS) MEVAC-A Completes Tender For Bangladesh 3
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... use in settings where a more secure band is ... but difficult to remove wristband is appropriate. The design ... time. One band to be placed on the wrist ... the first need to be replaced. This is particularly ...
IDENTI-MATCH II is a combination of the IDENTI-MATCH Blood Recipient Identification System and an admitting band. It has been designed for those facilities using label-based patient ID systems....
Zebras H 2824-Z Healthcare Starter Kit includes everything you need to start printing wristbands today: the H 2824-Z direct thermal printer, a pre-installed Media Adapter Guide, and a roll of adult-s...
... VerdaSees Navigaton™ software facilitates real time ... two modules: the first module is ... reader devices and the database where ... second module is the user interface, ...
Medicine Products: